Orchestra BioMed Holdings, Inc. (OBIO)
(Delayed Data from NSDQ)
$2.44 USD
-0.07 (-2.79%)
Updated Sep 19, 2025 04:00 PM ET
After-Market: $2.43 -0.01 (-0.41%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth A Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
OBIO 2.44 -0.07(-2.79%)
Will OBIO be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for OBIO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for OBIO
Orchestra BioMed Holdings, Inc. (OBIO) Reports Q2 Loss, Beats Revenue Estimates
CRISPR Therapeutics AG (CRSP) Reports Q2 Loss, Lags Revenue Estimates
OBIO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Orchestra BioMed Holdings, Inc. (OBIO) Reports Q1 Loss, Tops Revenue Estimates
Ultragenyx (RARE) Reports Q1 Loss, Misses Revenue Estimates
Orchestra BioMed Holdings, Inc. (OBIO) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Other News for OBIO
The technical outlook for OBIO is unchanged after it falls 2.79% on September 19
Stochastic Buy Signal appears for OBIO after 2.03% move
Technical picture remains unchanged for OBIO after it falls 2.77% on September 17
OBIO falls 2.69% on September 16, leaving the technical picture intact
Is OBIO signaling selling opportunity? 20 Day Moving Average Resistance shows up after rising 1.17%